Search Within

Population Sciences Research Program

  1. "Matthew Matasar"
  2. "Survivorship Research"
  3. "Molecular Imaging and Therapy Service"
  4. "Biostatistics Service"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (5)
Groups
  1. Biostatistics Service (14)
  2. Center for Hematologic Malignancies (14)
  3. Department of Medicine (14)
  4. Epidemiology and Biostatistics (14)
  5. Hematologic Malignancies, Division of (14)
  6. Lymphoma (14)

More Groups

People
  1. Matthew Matasar (14)
  2. Anas Younes (13)
  3. Andrew Zelenetz (13)
  4. Steven Horwitz (13)
  5. Alison Moskowitz (12)
  6. Anita Kumar (12)

More People

Years
  1. 2022 (2)
  2. 2021 (2)
  3. 2019 (1)
  4. 2017 (6)
  5. 2016 (2)
  6. 2014 (1)
Publications
  1. Blood (7)
  2. Hematological Oncology (3)
  3. Blood Cancer Journal (1)
  4. Clinical Cancer Research (1)
  5. Journal of Clinical Oncology (1)
  6. Journal of the American Heart Association (1)
Publishers
  1. American Society of Hematology (7)
  2. Wiley Blackwell (4)
  3. American Association for Cancer Research (1)
  4. American Society of Clinical Oncology (1)
  5. Nature Publishing Group (1)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Late gadolinium enhancement cardiac magnetic resonance tissue characterization for cancer-associated cardiac masses: Metabolic and prognostic manifestations in relation to whole-body positron emission tomography
    Journal Article

    Chan, A. T.; Fox, J.; Perez Johnston, R.; Kim, J.; Brouwer, L. R.; Grizzard, J.; Kim, R. J.; Matasar, M.; Shia, J.; Moskowitz, C. S.; more...
    Journal of the American Heart Association (2019)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save